AlphaQuest LLC Sells 5,329 Shares of Celcuity, Inc. $CELC

AlphaQuest LLC trimmed its stake in Celcuity, Inc. (NASDAQ:CELC) by 67.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,565 shares of the company’s stock after selling 5,329 shares during the period. AlphaQuest LLC’s holdings in Celcuity were worth $26,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CELC. Wells Fargo & Company MN lifted its stake in shares of Celcuity by 81.7% in the 4th quarter. Wells Fargo & Company MN now owns 15,515 shares of the company’s stock valued at $203,000 after purchasing an additional 6,976 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Celcuity during the 4th quarter worth approximately $167,000. The Manufacturers Life Insurance Company bought a new stake in shares of Celcuity during the 4th quarter worth approximately $142,000. Northern Trust Corp lifted its stake in shares of Celcuity by 16.4% during the 4th quarter. Northern Trust Corp now owns 300,076 shares of the company’s stock worth $3,928,000 after acquiring an additional 42,186 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Celcuity by 45.9% during the 4th quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company’s stock worth $5,853,000 after acquiring an additional 140,642 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director directly owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 15.77% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CELC has been the subject of a number of research analyst reports. Leerink Partners raised their price target on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, July 28th. Needham & Company LLC decreased their price target on Celcuity from $74.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, August 15th. HC Wainwright raised their price target on Celcuity from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Monday, August 18th. Finally, Stifel Nicolaus initiated coverage on Celcuity in a research note on Tuesday, July 1st. They set a “buy” rating and a $30.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $56.50.

Celcuity Trading Up 2.2%

Shares of NASDAQ CELC opened at $55.69 on Friday. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 2.24. The business has a fifty day simple moving average of $34.32 and a two-hundred day simple moving average of $18.84. The firm has a market cap of $2.36 billion, a PE ratio of -16.14 and a beta of 0.72. Celcuity, Inc. has a twelve month low of $7.57 and a twelve month high of $57.48.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). Analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.